The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2025 | Unmet clinical needs in CNS lymphomas: older patients and chemorefractory disease
Andrés Ferreri, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, highlights the key challenges in treating central nervous system (CNS) lymphomas. He mentions two groups of patients for which there is an unmet clinical need: older patients and those with chemorefractory disease. This interview took place at the SOHO Italy Annual Conference 2025 in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the most important challenges regarding in particular the patients older than 70 years, because this is a group of patients with several limitations. When we have to discuss about the treatment, in particular the intensity of induction or the toxicity related to the consolidation of autologous transplant and radiation therapy. In particular, the brain irradiation in patients over 60 years old is associated with an increasing risk of severe cognitive decline...
So the most important challenges regarding in particular the patients older than 70 years, because this is a group of patients with several limitations. When we have to discuss about the treatment, in particular the intensity of induction or the toxicity related to the consolidation of autologous transplant and radiation therapy. In particular, the brain irradiation in patients over 60 years old is associated with an increasing risk of severe cognitive decline. And in the elderly patients, the use of [inaudible] conditioning and the autologous transplantation is a strategy that should be limited only to highly selected patients. Then this is an important unmet clinical need. The other one is also the treatment of patients with chemorefractory disease. Patients who experience a progression during induction chemotherapy. In these patients, the prognosis is very poor because it is a very aggressive disease, usually with lower response rates with conventional chemotherapy and with biological agents.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
